The Patent Finder

Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy

Fondation Imagine

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,778,952Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy
In force
 · High confidence
Assistance Publique-Hôpitaux de Paris (Aphp)In forceHigh confidence
Application 17/280,620Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy
Abandoned
Abandoned Apr 8, 2024
Université Paris CitéAbandonedAbandoned Apr 8, 2024
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Fondation Imagine.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited